Thursday, Feb 27 2020 | Time 05:29 Hrs(IST)
  • Seven people dead in shooting in US state of Wisconsin - reports
  • Tunisian security forces kill 2 terrorists in preventive operation
  • Pakistan confirms first two coronavirus cases:Health Minister
  • MP Govt inks health deal with Tata
  • ‪Delhi violence : US, Russia issue security alert for their nationals
  • VP to inaugurate 'Thakurbari' on Mar 14 in Sikkim
Press Releases » Business Wire India

Major Study Proves Resolute Onyx DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk Patients with One-Month DAPT

Major Study Proves Resolute Onyx DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk Patients with One-Month DAPT
Resolute Onyx™ drug-eluting stent
Business Wire India

India Medtronic Private Limited, wholly-owned subsidiary of Medtronic plc (NYSE:MDT), today announced the clinical data from the Onyx ONE Global Study, representing the first prospective, multi-center, randomized study evaluating clinical outcomes between two drug-eluting stents (DES) in nearly 2,000 high-bleeding risk (HBR) patients with one month of dual antiplatelet therapy (DAPT).


In the study, Resolute Onyx met the primary composite endpoint of cardiac death, myocardial infarction (MI) or stent thrombosis (ST) at one-year demonstrating non-inferiority versus the comparator stent, BioFreedom™ Drug Coated Stent[i] – the only DES recommended by the European Society for Cardiology (ESC) in its guidelines for HBR patients that need one-month DAPT.


Results of Onyx ONE Global Study were first presented during a Late-Breaking Clinical Trial session at the 31st Transcatheter Cardiovascular Therapeutics Conference (TCT), the annual scientific symposium of the Cardiovascular Research Foundation in San Francisco held in September 2019.


“High bleeding risk patients are an important, growing and complex population which make up nearly 30-40% of PCI and have been often excluded from Drug Eluting Stent Trials.  The Onyx ONE study addresses this important ‘need of the hour’ by providing physicians with a comprehensive and robust data set that helps build highly effective treatment options with latest generation of thin strut Drug Eluting Stent (Onyx) for those patients who are at a high risk of bleeding and may be harmed by the longer course of DAPT", said Dr. Ashok Seth, Chairman of Fortis Escorts Heart Institute, New Delhi


The Onyx ONE Global Study is representative of complex clinical practice of HBR patients including those with anticoagulant use, renal failure, upcoming surgery, and recent blood transfusion. The study protocol did not exclude patients based on disease state or anatomical complexity. The Onyx ONE Global Study and Onyx ONE Clear Study make up the Medtronic Onyx ONE Month DAPT Program that has enrolled approximately 2,700 patients at up to 140 sites worldwide.


"Medtronic is committed to pioneering the practice of evidence-based medicine in the medical device industry in India. Resolute Onyx drug eluting stent continues to deliver excellent outcomes for a wide range of patients. To date, more than 20,000 patients have been studied in Medtronic clinical trials that have addressed DAPT duration. Having completed 40 years in India, Medtronic’s vision remains anchored on introducing innovations that continue to alleviate pain, restore health and extend life. We are happy to continue serving patients and improving lives through world class therapies that are backed by robust clinical data”, said Madan Krishnan, vice president, Medtronic Indian Subcontinent.


In addition to meeting the primary endpoint, the study showed superior acute performance2 for Resolute Onyx versus BioFreedom, with superior device success of 92.8% versus 89.7%, respectively [p=0.007]. At one year, there was low (2.8%) target lesion revascularization (TLR) for Resolute Onyx versus 4.0% for the comparator stent. Additionally, stent thrombosis (ST) for Resolute Onyx was low (1.3%) versus BioFreedom (2.1%).


A landmark analysis conducted after discontinuation of DAPT at one month showed low event rates for Resolute Onyx3. At one year, the composite endpoint (cardiac death, ST, myocardial infarction [MI]) of this analysis was 7.5% for Resolute Onyx vs. 8.8% for BioFreedom. Additionally, there was significantly lower MI – 4.3% for Resolute Onyx™ versus 6.8% for BioFreedom (p < 0.01).


The Resolute Onyx DES encourages fast vessel healing with its proprietary BioLinx™ polymer, a bio-compatible and non-thrombogenic coating created specifically for use on DES and unique platform design featuring Continuous Sinusoid Technology (CST), which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. The Resolute Onyx DES received CE (Conformité Européene) Mark in September 2014 and FDA approval in April 2017.


In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to the healthcare consumers and providers around the world.

[i] BioFreedom is not currently approved for use in the United States.

2 Acute performance parameters were not powered or adjusted for multiplicity.

3 Post-hoc landmark analyses were not powered.

The Resolute Onyx DES is not contraindicated for high bleeding risk patients and there are no precautions listed in the IFU that would preclude high bleeding risk patients from intervention.

More News

Wipro positioned as Leader in Everest Group - Life Sciences Digital Services PEAK Matrix™ Assessment

26 Feb 2020 | 5:33 PM

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a ‘Leader’ in Everest Group’s Life Sciences Digital Services PEAK Matrix™ Assessment 2019, globally.

see more..

Frost and Sullivan in Partnership With VMware Unveils the Hybrid Cloud Maturity Index (HCMI) Assessment for Enterprises

26 Feb 2020 | 4:39 PM

VMware, Inc. (VMW), a leading innovator in enterprise software, along with Frost & Sullivan, leading global research and consulting firm, released the Hybrid Cloud Maturity Index (HCMI) 2019 assessment of enterprises.

see more..

Important Things to Know About CIBIL Score for a Personal Loan

26 Feb 2020 | 2:40 PM

Personal loans are becoming a popular avenue of financing as they don’t require any asset to be pledged as security and can be applied for easily online.

see more..
US-India Strategic Partnership Forum Hosts the Strategic and Business Dialogue During President Donald J  Trump’s Visit to India

US-India Strategic Partnership Forum Hosts the Strategic and Business Dialogue During President Donald J Trump’s Visit to India

26 Feb 2020 | 1:59 PM

During President Trump’s maiden India visit, the US-India Strategic Partnership Forum (USISPF) launched the US-India Tax Forum, an initiative designed for industry and government to engage on global and local tax policy issues.

see more..

Here’s Why You Must Opt for a Hospital Cash Plan From Bajaj Finserv

26 Feb 2020 | 12:13 PM

Offered by Bajaj Finance Limited, the lending arm of Bajaj Finserv, the Hospital Cash Cover provides a daily cash allowance to take care of the day-to-day expenses. The daily cash benefit can also be availed if one is undergoing a day care treatment procedure.

see more..